Central to sialylation regulation is the dynamic balance betweensialidases (which remove terminal sialic acids) and sialyltransferases(STs) (which catalyze sialylation of glycans). Critically, the pathological overexpression of STs hasbeen shown to be the principal driver of tumor-associated hypersialylation, prompting intensive research into developingST-targeted inhibitors for potential anticancer therapeutics.−, , , ,. Here, STS is linked to neoplasm.